Jonathan Rios-Doria; Jay Harper; Raymond Rothstein; Leslie Wetzel; Jon Chesebrough; Allison Marrero; Cui Chen; Patrick Strout; Kathy Mulgrew; Kelly McGlinchey; Ryan Fleming; Binyam Bezabeh; John Meekin; David Stewart; Maureen Kennedy; Philip Martin; Andrew Buchanan; Nazzareno Dimasi; Emil Michelotti; Robert Hollingsworth
Gholamin and colleagues treated malignant pediatric brain tumor models with a humanized anti-CD47 antibody (Hu59-G4). In primary and metastatic high-risk medulloblastoma, Hu5F9-G4 inhibited growth in vivo , including CD15-positive putative medulloblastoma stem cells. Because children with g ... more
In this article [(Cancer Res 2016;76:5756–67)], which appeared in the October 1, 2016, issue of Cancer Research (), there are errors in Figs. 2A and 6E. The authors used one trimmed image/blot to fit the size of the others. In these two panels, they accidentally kept the “ruler image/ more
Checkpoint inhibitors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alterations and a T-cell–inflamed phenotype. One significant barrier to efficacy may be the recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment. He ... more
In a phase Ia clinical trial, immune cells called Tregs, which can inhibit anticancer immune responses, were efficiently eliminated from the blood of patients with lung or esophageal cancer by treatment with the investigational therapeutic antibody KW-0761.
Author(s): Ryuzo Ueda, MD, PhD, p ... more